1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Sydnee Gatewood
Sydnee Gatewood
Articles (607) 

Andreas Halvorsen Takes Stake in Eidos Therapeutics

Guru invests in newly public biopharmaceutical company

Viking Global Investors leader Andreas Halvorsen (Trades, Portfolio) disclosed he established a 5.5% stake in Eidos Therapeutics Inc. (NASDAQ:EIDX) on June 22.

According to GuruFocus real-time picks, Halvorsen, who picks stocks based on his understanding of the business' fundamentals, management team and cyclical and secular industry trends, invested in 1.9 million shares of Eidos for an average price of $21.90 per share, giving the holding 0.26% portfolio space.

The San Francisco-based clinical-stage biopharmaceutical company, which went public on June 20, has a market cap of $752.1 million; its shares were trading around $21 on Tuesday, up 3.35%. Since its initial public offering, the stock has fallen from its opening day closing price of $23.12.

GuruFocus estimates Halvorsen has lost approximately 4% on the investment so far. No other gurus have positions in the stock.

About the company

Eidos Therapeutics focuses on developing treatments for diseases caused by transthyretin amyloidosis, which is, according to the U.S. National Library of Medicine, a progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid in the body’s organs and tissues.

The company says on its website that there are currently no Food and Drug Administration-approved treatments for this condition. It is hoping to change that with AG10, a novel therapeutic that targets the disease by stabilizing transthyretin, a transport protein secreted by the liver and choroid plexus.

Valuation

GuruFocus rated Eidos’ financial strength 5 out of 10 and its profitability and growth 2 out of 10.

While the company has no debt, GuruFocus warns its Sloan ratio of -34.23% indicates it has poor earnings quality. Further, its negative returns underperform the majority of its competitors.

Portfolio

Managing $25 million in assets, the Greenwich, Connecticut-based hedge fund’s portfolio, which is composed of 59 holdings, is largely invested in the technology sector, followed by financial services and health care.

Other biotech stocks Halvorsen is invested in are Biomarin Pharmaceutical Inc. (NASDAQ:BMRN), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), AnaptysBio Inc. (NASDAQ:ANAB), Abeona Therapeutics Inc. (NASDAQ:ABEO), Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH), AveXis Inc. (NASDAQ:AVXS), Editas Medicine Inc. (NASDAQ:EDIT) and aTyr Pharma Inc. (NASDAQ:LIFE).

In 2017, Halvorsen was ranked the eighth-highest-earning hedge fund manager in the world, recording $26 billion in net gains since inception.

Disclosure: No positions.

About the author:

Sydnee Gatewood
I am an editorial assistant at GuruFocus. I have a BA in journalism and a MA in mass communications from Texas Tech University. I have lived in Texas most of my life, but also have roots in New Mexico and Colorado. Follow me on Twitter! @gurusydneeg

Rating: 5.0/5 (2 votes)

Voters:

Comments

Please leave your comment:


Performances of the stocks mentioned by Sydnee Gatewood


User Generated Screeners


Marcelo SommerBrazil - High Piotroski
johnbarberHF_Stalwarts
pbarker46Dividend basic
aboer52-41 Downies
aboer52-29 DN Prof▼5Pred▼1Pi▼5J
aboer52-36 Bottom 20% of industries
aboer52-165 Bad ROE
aboer52-225 dn Op Mgn < 20th percenti
aboer52-451 dn Warn><1 Finan<6 Profit
aboer52-88 Profit<=5 Warnings >=3
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK